• Amylyx priced an upsized underwritten public offering of 14,090,000 common shares at USD 35.5 each.
• Gross proceeds expected at about USD 500.2 million, before discounts and offering expenses.
• Underwriters received a 30-day option to buy up to 2,113,500 additional shares.
• Net proceeds earmarked for avexitide pre-commercial work, research and development, working capital, general corporate purposes.
• Closing expected on or about Aug. 21, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.